# A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

Study · id `cardio:ct-nct07222917` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07222917](<https://clinicaltrials.gov/study/NCT07222917>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07222917

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 222 participants.

## Technical summary

Registry record NCT07222917. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-05 (actual); primary completion 2026-12-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 222 participants (enrolled count; ClinicalTrials.gov record NCT07222917, source copy `cardio:ctgov-nct07222917-2026-09-01`, retrieved 2026-10-26)
- Started: 2025-12-05 (actual) (ClinicalTrials.gov record NCT07222917, source copy `cardio:ctgov-nct07222917-2026-09-01`, retrieved 2026-10-26)
- Primary completion: 2026-12-10 (anticipated) (ClinicalTrials.gov record NCT07222917, source copy `cardio:ctgov-nct07222917-2026-09-01`, retrieved 2026-10-26)
- Completion: 2026-12-10 (anticipated) (ClinicalTrials.gov record NCT07222917, source copy `cardio:ctgov-nct07222917-2026-09-01`, retrieved 2026-10-26)
- Countries: United States; Argentina; Bulgaria; Canada; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT07222917, source copy `cardio:ctgov-nct07222917-2026-09-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07222917-2026-09-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
- Acronym: BaxDuo-Baltic
- Condition: Chronic Kidney Disease and Hypertension
- Intervention (Drug): Baxdrostat/dapagliflozin
- Intervention (Drug): Baxdrostat/Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 5663bae52b82c87a733bd0c06adeca0b1db7a2aab11a071465a91a89fba5f8af
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
